Brivaracetam Film-coated tablet + Brivaracetam oral solution

Phase 3Completed

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Childhood Absence Epilepsy

Conditions

Childhood Absence Epilepsy, Juvenile Absence Epilepsy

Trial Timeline

Mar 30, 2022 → Mar 18, 2025

NCT ID

NCT05109234

About Brivaracetam Film-coated tablet + Brivaracetam oral solution

Brivaracetam Film-coated tablet + Brivaracetam oral solution is a phase 3 stage product being developed by UCB for Childhood Absence Epilepsy. The current trial status is completed. This product is registered under clinical trial identifier NCT05109234. Target conditions include Childhood Absence Epilepsy, Juvenile Absence Epilepsy.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06315322	Phase 3	Recruiting	Jul 10, 2024	Mar 1, 2030	Childhood Absence Epilepsy
NCT05109234	Phase 3	Completed	Mar 30, 2022	Mar 18, 2025	Childhood Absence Epilepsy

Competing Products

20 competing products in Childhood Absence Epilepsy

See all competitors

Product	Company	Stage	Hype Score
LY2940680 + LY2940680	Eli Lilly	Phase 1	33
Panobinostat + Cytarabine + Panobinostat	Novartis	Phase 1	33
Obinutuzumab + MMF + Prednisone + Methylprednisolone + Acetaminophen/ Paracetamol + Diphenhydramine Hydrochloride	Roche	Phase 3	77
Rituximab + Placebo	Roche	Phase 2/3	65
Blinatumomab	Amgen	Phase 2	51
Semaglutide	Novo Nordisk	Approved	84
Temsirolimus + Etoposide + Cyclophosphamide + Methotrexate + Hydrocortisone + Cytarabine	Pfizer	Phase 1	32
Talazoparib + Irinotecan + Temozolomide + Filgrastim + Peg-filgrastim	Pfizer	Phase 1	32
Crizotinib	Pfizer	Phase 1/2	40
Nivolumab + 5-azacytidine	Bristol Myers Squibb	Phase 1/2	40
carboplatin + irinotecan hydrochloride	Bristol Myers Squibb	Phase 1	32
Vinblastine + Cyclophosphamide + Capecitabine + Nivolumab	Bristol Myers Squibb	Phase 1/2	40
Paxalisib + Opdualag + Irinotecan (drug) + Temozolomide (TMZ)	Bristol Myers Squibb	Phase 1/2	40
Clofarabine incorporated into a 5-drug regimen	Sanofi	Phase 1	32
Brivaracetam Film-coated tablet + Brivaracetam oral solution	UCB	Phase 3	74
Brivaracetam	UCB	Phase 3	74
Sodium Oxybate	Jazz Pharmaceuticals	Phase 1/2	38
Modified Measles Virus + Modified Measles Virus Lumbar Puncture	Brain Biotech	Phase 1	25
palbociclib isethionate	Brain Biotech	Phase 1	25
Cytarabine + Fludarabine + Hydrocortisone Sodium Succinate + Imetelstat + Leucovorin Calcium + Methotrexate	Geron	Phase 1	28

Other Products from UCB

LevetiracetamApproved

Parcopa + carbidopa-levodopa (Sinemet)Approved

LevocetirizineApproved

RotigotineApproved

Levetiracetam + OxcarbazepineApproved